ATLANTA and TAIPEI, Jan. 13, 2025 /PRNewswire/ — Cambium Oncology and Orient Euro Pharma (OEP) announce a strategic partnership in which OEP has invested $5M in Cambium Oncology. This will accelerate the clinical development of Cambium Oncology’s lead therapeutic candidate, ANT308, a…

Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancers Financials include a $13 million upfront payment and potential for significant further milestones HELSINKI, Jan. 13, 2025 /PRNewswire/ — Rappta Therapeutics…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.